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Abstract: Background. Human T-cell lymphotropic virus type 1 (HTLV-1) is responsible for tropical
spastic paraparesis and HTLV-1-associated leukemia/lymphoma. The infection is endemic in some
areas of Peru, but its prevalence in the Peruvian Amazon is not well established. We aimed to assess
the seroprevalence of HTLV-1 infection in pregnant women in the Peruvian Amazon. Moreover, we
performed a systematic literature review and meta-analysis of the seroprevalence of HTLV infection
in Peru. (2) Methods. This is a prospective cross-sectional study involving pregnant women attending
health centers in the city of Iquitos, Peru, in May and June 2019. The presence of antibodies against
HTLV-1 was assessed using ELISA (HTLV I + II ELISA recombinant v.4.0, Wiener lab, Rosario, Argentina).
Positive cases were confirmed by Western Blot and HTLV-1 proviral load. (3) Results. The study included
300 pregnant women with a mean age of 26 years (standard deviation [SD] 6.4). Five patients were
diagnosed with HTLV-1 infection (prevalence 1.7%, 95% confidence interval (CI) 0.7% to 3.8%). Pregnant
women with HTLV-1 infection were discretely younger (mean age 22.6 [SD 22.6] vs. 26.8 [SD 6.3];
p = 0.128). None of the five women had been transfused, and all were asymptomatic. Two (40%) also
had a positive serology for Strongyloides, but larvae were not detected in any of the parasitological stool
studies. The systematic review component identified 40 studies, which showed that the prevalence of
HTLV infection in the general population was 2.9% (95% CI 1.2% to 5.3%) and in women of childbearing
age, 2.5% (95% CI 1.2% to 4.0%). (4) Conclusion. The prevalence of HTLV-1 in the Peruvian Amazon
basin is about 1.7%, indicating an endemic presence. Screening for HTLV-1 in prenatal care is warranted.
Keywords: HTLV; prevalence; pregnant women; Peru; Amazon; systematic review
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1. Introduction
Human T-cell lymphotropic virus (HTLV) was the first human retrovirus identified. It
is mostly sexually transmitted [1] but it can also be shed perinatally by breastfeeding [2]
and parenterally through contaminated blood, either following transfusions or by needle
sharing among injection drug users [3]. Acute infection with HTLV-1 is followed by long-
lasting persistence of the virus in all carriers, although clinical manifestations develop only
in about 10%. Typically, it presents as a subacute myelopathy known as tropical spastic
paraparesis/HTLV-1-associated myelopathy [4] or a lymphoproliferative disorder named
adult T-cell leukemia/lymphoma (ATLL) [5].
HTLV can spread through mother-to-child transmission (MTCT), mainly through
breastfeeding. As this is one of the main mechanisms of transmission in endemic areas,
systematic HTLV antenatal screening is carried out in some countries, such as Japan and
a few Latin American countries like Brazil [6,7]. Mothers found to be HTLV positive are
advised to substitute breastfeeding with formula feeding for their infants [6].
Worldwide, approximately 5 to 10 million people are infected with the human T-cell
lymphotropic virus type 1 (HTLV-1) [8,9]. A large proportion of these people are in Central
and South America, where the disease is endemic. In Peru, HTLV-1 prevalence in candidate
blood donors varies from 1.2% to 1.7% across regions, with higher figures for some Andean
areas [10]. Most studies have taken place in Lima or the Andes [11–13], whereas there are
scant data from the Amazon [11,14–16].
Knowledge on the prevalence of HTLV-1 is vital for understanding whether antenatal
screening is justified in the Amazon Basin, so that infected mothers can avoid breastfeeding
to effectively prevent vertical HTLV transmission. Thus, this study aimed to assess the
seroprevalence of HTLV-1 infection in pregnant women in the Peruvian Amazon. In
addition, we undertook a systematic literature review and comprehensive review of the
incidence of HTLV-1 in Peruvian cohorts and meta-analyzed the seroprevalence of HTLV
infection in Peru.
2. Results
2.1. HTLV Infection in Pregnant Women
We included 300 pregnant women with an average age of 26 years (standard deviation
[SD] 6.4 years). The mean number of deliveries was 2.9 (SD 1.7), and the mean gestation
period, 172 days (SD 59). Just under half (44.7%) lived in peri-urban areas, while the rest
lived in the city.
Five patients were diagnosed with HTLV-1 infection by serology (prevalence 1.7%,
95% confidence interval [CI] 0.7% to 3.8%). Pregnant women with HTLV-1 infection were
slightly younger (mean age 22.6 [SD 22.6] years vs. 26.8 [SD: 6.3] years; p = 0.13). None of the
five women with HTLV-1 had been transfused, had a tattoo, or had a history of leukemia or
neoplasm. All of them with other children had breastfed in the past. Strongyloides serology
was positive in 2 of the 5 pregnant women (40%); however, the parasitological study
in stool was negative for Strongyloides larvae in all of them. All HTLV-infected women
were asymptomatic.
The characteristics of the five positive cases are summarized in Table 1. The numbers of
HTLV-1 pro-viral copies were evaluated in four patients, who presented 3324 copies/10,000 cells,
950 copies/10,000 cells, and <10 copies/10,000 cells; in one, the proviral load was undetectable.
No data were available for the remaining patient.
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Table 1. Characteristics of five cases of human T-cell lymphotropic virus (HTLV) infection in pregnant women in greater
Iquitos, Peru, diagnosed with ELISA serology.







1 19 88 Primipara Urban HTLV-1 Not available Positive
2 35 181 Multipara Urban HTLV-1 950 Negative
3 20 233 Multipara Urban HTLV-1 Undetectable Negative
4 20 274 Primipara Periurban HTLV-1 <10 Negative
5 19 63 Multipara Periurban HTLV-1 3324 Positive
2.2. Systematic Review and Meta-Analysis of the Prevalence of HTLV Infection in Peru
The electronic search in PubMed and SciELO yielded 135 records, while a further
6 studies were identified from other sources. After screening the abstracts, we examined
the full text of 61 potentially relevant papers, excluding 21 that did not report data on
HTLV-1 prevalence. Therefore, the total number of included papers was 40 studies, plus
the present study (Figure 1). Figure 1 shows the flow chart for study selection.
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Table 2 summarizes the characteristics of the studies from our literature review of
HTLV prevalence in Peru [10,11,13–50]. Some studies were performed in the general popu-
lation cohorts (including prisoners or hospital inpatients), as well as specific populations,
like pregnant women or women of childbearing age, sex workers, people with HIV infec-
tions, men who have sex with men (MSM), relatives or descendants of people infected
with HTLV, people with Strongyloides infections, people infected with tuberculosis, and
blood donors.
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Table 2. Peruvian studies of HTLV prevalence.
Study ID Setting(s)/(Department) Population
Prevalence
HTLV-1 Diagnostic Procedure




Wignall 1992 [11] Callao (Lima)Iquitos
395 sex workers in Callao
72 sex workers in Iquitos





-EIA (Cambridge Bioscience; Worchester, MA)
-Western blot (DuPont; Wilmington, DE)
-RIPA
Gottuzo 1992 [13] Lima 111 men with HIV 18% -ELISA (Cambridge Bioscience Worcester, Mass)-Western blot (DuPont, Wilmington, Del)
Hyams 1993 [18] Callao (Lima) 966 sex workers 17.6%
-ELISA (Cambridge Bioscence, Worcester, MA, USA)
-Western blot (DuPont, Wilmington, DE, USA)
-RIPA
Gotuzzo 1994 [19] Lima 400 sex workers 7% -ELISA (Genetic Systems, Seattle).-Western blot (Cambridge Biotech, Worcester, MA)
Trujillo 1996 [20] Lima 158 sex workers 3.8%
-ELISA (Cambridge Biotech, Worcester, MA)
-Western blot (Cambridge Biotech, Worcester, MA)
Gotuzzo 1996 [21] Lima 407 (280 women and 127 men) Japanesemigrants and their children in Peru
6.8% women
3.2% men
-ELISA (Gentic Systems, Seattle, WA)
-Western blot (Cambridge Biotech, Worcester, MA)











-ELISA (Genetic Systems, Seattle, WA)
-Western blot (Cambridge Biotech, Worcester, MA)
Garrido 1997 [23] Pisco–Ica 54 MSM32 Sex workers
1.9%
10.4%
-ELISA (Genetic Systems, Seattle)
-Western blot (Cambridge Biotech, Worcester, MA)
Muñoz 1997 [24] Lima 298 non-intravenous drug users 2.3% -ELISA (Cambridge Biotech, Worcester, MA)-Western blot (Cambridge Biotech, Worcester, MA)
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Table 2. Cont.
Study ID Setting(s)/(Department) Population
Prevalence
HTLV-1 Diagnostic Procedure
Medeot 1999 [16] Peruvian Amazon 456 participants 0.44%
-Particle agglutination (PA) technique (Serodia; Fujirebio, Inc., Tokyo,
Japan)
-IFA
-Western blot (Problot-HTLV-1; Fujirebio, Inc)
Fujiyoshi 1999 [25] Peru 66 participants from the Aymara ethnicgroup 1.6%
-Particle agglutination (PA) (Serodia HTLV-1, Fujirebio, Tokyo, Japan)
-Western blot (HTLV Blot 2.3/HTLV Blot 2.4; Diagnostic Biotechnology,
Singapore)
Zunt 1999
[26] Callao (Lima) 255 sex workers 13%
-ELISA (Cambridge Bioscience, Worcester, MA)
-Western blot (Cambridge Bioscience)
Gotuzzo 1999
[27] Lima
21 Strongyloides hyperinfection patients
21 healthy controls







-Western blot (DuPont, Wilmington, DE)
Garcia 2002 [28] Lima
400 prisoners (EPCROL)







[29] Lima 1119 sex workers 8.7%
-ELISA (Cambridge Bioscience)







-ELISA (Platelia HTLV-I New, Sanofi Diagnostics Pasteur, Paris, France)
-IFA (California Department of Health Services, Berkeley, CA, USA)
-RIBA (Chiron Corporation, Emeryville, CA, USA)
-Western blot (WB, Cambridge Biotech, Worcester, MA, USA)
-PCR (Belgium, AM Vandamme)
Verdonck 2004




[32] Lima 67 children exposed to HTLV-1 18%
-ELISA (Platelia HTLV-1; Sanofi Pasteur)
-Western blot (Genelabs Diagnostics)








-Inno-LIA HTLV I/II score (Innogenetics, Ghent, Belgium)
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Table 2. Cont.




[34] Lima 23 Norwegian scabies patients 69.6%
-ELISA (Cambridge Bioscience, Worcester, MA)
-Western immunoblot (DuPont, Wilmington, DE)
Laguna-Torres 2005
[35] Lima y Cuzco 351 multi-transfused patients 3.1%
-ELISA (Vironostika)
-lmmunoblot techniques (HTLV blot 2.4 Genelabs Diagnostic)









-Western blot (HTLV-I/II blot 2.4;
Genelabs Diagnostics, Singapore)
Zunt 2006
[38] Lima 53 myelopathy patients 81%
-ELISA (Cambridge Bioscience, Worcester, MA)
-Western blot (Genelabs Diagnostics, Singapore)
Gotuzzo 2007 [39] Lima 370 descendants of mothers infectedwith HTLV-1
19% (there were 641
descendants, but
only 370 agreed to be
tested)
-ELISA (Sanofi
Diagnostics Pasteur, France; Bio-Rad Laboratories, U.S.A.; or
Cambridge
Biotech, USA)




[40] Lima 311 tuberculosis patients 5.8%
-ELISA (Ortho y Platelia)
-Inno-LIA




-ELISA (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France;
Bio-Rad Laboratories, Hercules, CA, USA; or Cambridge Biotech,
Worcester, MA, USA)
-Western blot (Genelabs Diagnostics, Singapore)
Quispe 2009 [10] Arequipa 2732 blood donors 1.2%
-ELISA (Vironostika HTLV-I/II, BioMerieux, France)
-BioELISA HTLV-I+II (BioKit S.A., Spain)
-Western blot (WB 2.4, Genelabs Diagnostics, Singapore)
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Table 2. Cont.
Study ID Setting(s)/(Department) Population
Prevalence
HTLV-1 Diagnostic Procedure




2655 MSM 1.8% -ELISA (Vironostika)-Western blot (HTLV-I/II blot 2.4; Genelabs Diagnostics, Singapore)
Collins 2009
[43] Lima 1456 HIV patients 5%
-EIA (Sanofi Pasteur, France or Abbott, USA)
-Western blot (Cambridge Biotech, USA or DAVIH-Blot, Cuba)
Delgado 2011
[44] Lima 44 herpes zoster patients 5% -ELISA (Ortho)
Alva 2012 [14]
10 indigenous groups in
the Amazon less than




638 participants 1.9% -ELISA (Vironostika, NC)-Western blot (HTLV-1/2 Blot 2.4; Genelabs Diagnostics, Singapore)
Carcamo 2012 [45]
24 cities with more than
50,000 inhabitants.
Branch of the PREVENT
trial
1530 serum samples from participants
aged 18 to 29 years old 0.3%
-ELISA (Vironostika, Durham, NC, USA)
-Western blot 2·4 (Genelabs Diagnostics, Science Park, Singapore)
Mayer 2013
[46] Lima
893 adults (428 close relatives of a
person with HTLV-1 infection, 118 with
neurological disorder, 160 with
strongyloidiasis, and 181 others)
26.4%
-ELISA (Murex, Ortho y Platelia)
-Western blot
-Inno-LIA
Blas 2013 [47] Lima and Pucallpa 1253 women of the Shipibo-Koniboethnic group 5.9%
-HTLV ELISA (Vironostika, North Carolina)
-Western blot (HTLV-1/2 Blot 2.4, Genelabs Diagnostics, Singapore)
Ita 2014 [48] Provinces of Cangallo,Vilcashuaman and
Parinacochas (Ayacucho)
397 participants 2.8%
-ELISA HTLV I+II Murex Biotech Ltd., Dartford, UK.
-HTLV-I/HTLV-II Ab.capture ELISA test system (Ortho Clinical
Diagnostic, Amersham, UK)
-Inno-LIA HTLV-I/II Score (Innogenetics, Ghent, Belgium)
-Western blot HTLV Blot 2.4 (MP Diagnostics, Singapore)
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Table 2. Cont.
Study ID Setting(s)/(Department) Population
Prevalence
HTLV-1 Diagnostic Procedure
Stewart 2017 [49] Callao (Lima)
1918 sex workers (n = 1477 in period 1,
n = 62 in period 2, and n = 379 in period
3)
9.6%
-HTLV EIA (Cambridge Bioscence, Worcester, MA)
-Western blot (Cambridge Bioscence)
-Vironostika HTLV I/II Microelisa System, Organon
Teknika/Biomérieux, Durham, NC
-HTLV I/II Western blots (Genelabs Diagnostics, Singapore)
-Bioelisa HTLV I/II 5.0, Biokit, Barcelona, Spain
-HTLV I/II score; Innogenetics, Ghent, Belgium
Ramirez-Soto 2018 [50] Abancay 2895 blood samples 3.4% -ELISA (Biokit, Barcelona, Spain)
Cabezas 2020




(present study) Iquitos 300 pregnant women 1.7%
-ELISA (HTLV I+II ELISA recombinante v.4.0, Wiener lab, Rosario,
Argentina)
HTLV: human T-cell lymphotropic virus; STI: sexual transmitted infection, MSM: men who have sex with men; PCR: polymerase chain reaction; WB: Western blot.
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The pooled proportion of HTLV in the general population was 2.34% (95% CI 1.96% to
2.75%; I2 95.51%). Table 3 summarizes the results of pooled prevalence in different groups,
assuming a random-effects model. As expected, we found high heterogeneity with the
exception of studies related to tuberculosis-infected patients. Figures 2 and 3 summarize
the forest plot prevalence in different groups.
Table 3. Pooled prevalence of HTLV infection in different population groups.
Population Group Pooled Prevalence 95% CI I2%
Pregnant women 0.025 0.012–0.040 90.7
Sex workers 0.093 0.056–0.137 92.9
HIV infection 0.104 0.013–0.64 94.8
Men who have sex with men 0.033 0.009–0.069 97.1
Relatives/descendants of HTLV patients 0.225 0.155–0.304 94.7
Strongyloides infections 0.300 0.003–0.792 96
Tuberculosis 0.065 0.045–0.088 0
Blood donors 0.021 0.005–0.048 96.8
General population 0.029 0.012–0.053 95.4
Subgroup differences: total Chi2 = 2.44 |Chi| = 49.68 (8 degrees of freedom) p < 0.001.
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Figure 3. Forest plot of pooled prevalence of HTLV (random effects) in (a) descendants and relatives of HTLV patients,
(b) people with Strongyloides infection, (c) people living with HIV, (d) people infected with tuberculosis, and (e) blood donors.
3. Discussion
Few studies on the prevalence of HTLV have been carried out in pregnant women
in Peru. In our study, the prevalence was 1.7%, which is lower than that reported by
Wignall et al. [11] and Zurita et al. [22], higher than in the study by Juscamaita et al. [33], and
similar to Alarcon et al. [36] a study involving 2492 pregnant women in Lima (the largest
sample size in the literature), which also reported a prevalence of 1.7%. The prevalence in
pregnant Peruvian women is higher than reported in other South American countries like
Argentina (0.19% to 2.25%) [51,52] or Brazil (0.10% to 1.70%) [53,54], and lower than that in
studies from French Guyana (4%) [55,56].
HTLV is effectively transmitted from mother to child, mainly through breastfeeding,
which is one of the main transmission routes in endemic areas. In fact, pooled prevalence
among descendants of HTLV-infected women has been estimated as high as 22.5% in the
Peruvian population. However, HTLV screening in women attending antenatal clinics in
endemic areas appears cost-effective [57], as preventing MTCT contributes to reducing
both the incidence of HTLV and the burden of HTLV-associated diseases [2].
In Peru, HTLV-1 infections are reported in 1.2% to 3.4% of potential blood donors [10,50].
Blood products have been screened for HTLV-1 since 1997 in this country, but there is
no specific program in pregnant women or neonates. The prevalence we observed in
pregnant women supports the need to implement measures to prevent MTCT. However, to
better understand the public health importance of HTLV infections, additional, adequately
powered studies examining HTLV seroprevalence across Peru are a priority [2].
The main risk factors for HTLV-1 infection, as described in the literature, are age
of more than 30 years, first sexual intercourse before the age of 20 years, and history of
abortion or transfusion [30,36,47]. In our study, most infected women had been sexually
active before the age of 20 years, but the rest of the factors did not seem to play a role.
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Two studies have examined the prevalence of HTLV-1 in the Peruvian Amazon: one
in remote indigenous communities, where the prevalence was 1.9% [14], and another in
sex workers in Iquitos, who showed a seropositivity of 4.2% [11]. Despite the geographical
proximity, the study populations were not comparable. The prevalence in our study was
lower than in either of these studies. Nevertheless, in a cross-sectional, population-based
study in 14 indigenous communities of the Matsés ethnic group in Requena province
(Loreto region), the prevalence was 0.6% lower than that in our study [15].
Incidence of Strongyloides infection in patients with HTLV is higher than that in
non-infected patients [58]. HTLV infection is considered a risk factor for S. stercoralis
dissemination, which can be fatal. S. stercoralis infection is related to HTLV-1 clonal ex-
pansion in asymptomatic individuals [59]. Moreover, in Peru, Gotuzzo et al. reported
HTLV infection in 85.7% of Strongyloides hyperinfection patients and 9.7% of patients with
intestinal Strongyloides infection [27]. In our study, Strongyloides serology was positive in
40% of pregnant women; however, the parasitological study in stool was negative. Testing
for antibodies against S. stercoralis is one strategy to identify a Strongyloides infection in
patients with a negative parasitological study (direct stool smears, the Baermann tech-
nique, the Harada-Mori filter paper culture, charcoal cultures, and nutrient agar plate
cultures) [60,61]. There is no clear explanation for the high seroprevalence of Strongyloides
in HTLV-infected women in our study. The Peruvian Amazon may be an endemic region
for Strongyloides, signaling high prevalence in the general population, including pregnant
women [60]. Future studies are needed to evaluate clinical and subclinical Strongyloides
infection in pregnant, HTLV-infected women.
The main strength of this study is its evaluation of HTLV-1 prevalence in pregnant
women in greater Iquitos, providing information that is relevant for monitoring the risk of
perinatal transmission through breastfeeding. This study has several limitations, Firstly,
it screened a small sample for a prevalence study, so differences in patient characteristics
between positive and negative cases could not be detected. Secondly, the proviral load
was determined retrospectively, and data could not be collected from one patient who
was not followed up. Thirdly, it was not possible to follow up the pregnant women and
recommend avoiding breastfeeding for preventing transmission.
We consider necessary a large study in the Peruvian Amazon to understand the
relevance of asymptomatic HTLV infections in pregnant women and the coinfection with
Strongyloides, to provide definitive evidence supporting implementation of screening in
pregnant women, as already in place for HIV and other viral infections.
4. Materials and Methods
4.1. Type of Study and Study Period
We performed a cross-sectional survey of HTLV-1 and strongyloidiasis in May and
June 2019.
4.2. Study Population and Data Collection
We included pregnant adults (≥18 years) attending health centers in four districts
of greater Iquitos, a city in the Peruvian Amazon. Participants were selected through
convenience sampling (i.e., on days when the researcher was at the health center) when
they visited the midwife for prenatal check-ups. Previous studies performed by our group
have reported details of the study population and data collection [60,62].
The presence of antibodies against HTLV-1 was assessed by ELISA (HTLV I+II ELISA
recombinant v.4.0, Wiener lab, Rosario, Argentina). Positive cases were confirmed by
Western blot and SYBR Green–based real-time quantitative polymerase chain reaction
(qPCR) assay, developed in the Institute of Tropical Medicine ‘Alexander von Humboldt’,
Peruvian University Cayetano Heredia, Lima [63]. Briefly, DNA from peripheral blood
mononuclear cells (PBMCs) was amplified by real-time PCR to detect and quantify HTLV-1
using the Light Cycler 480 II System (Roche Life Sciences). Genomic DNA was extracted
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from 5 × 106 PBMCs by a spin column using the QIAamp blood DNA mini kit (Qiagen,
Hilden, Germany).
Serology was processed for Strongyloides stercoralis with the Strongyloides IgG IVD-
ELISA kit (DRG Instruments GmbH, Marburg, Germany), while Baermann’s method and
charcoal culture were performed in stool specimens from HTLV-1 positive patients.
4.3. Data Analysis
Patient information was recorded in a Microsoft Excel database. The collected data were
analyzed using SPSS statistical software (version 22.0, IBM). We used the chi-squared test or
Fisher’s exact test to analyze the presence of HTLV infection according to several demographic
variables, considering results to be significant when the p value was less than 0.05.
4.4. Ethical Considerations
The Ethics Committee of the General University Hospital of Alicante (Spain) approved
the project (PI2018/113), as did the Ethics Committee of Loreto Regional Hospital in Iquitos
(Peru) (027-CIEI-HRL-2019). After receiving information on the study, individuals who
volunteered to participate gave their written consent and were included. All results were
kept strictly confidential, and participants with positive results were referred to their health
centers for assistance or treatment.
4.5. Literature Review of the Prevalence of HTLV Infection in Peru
We performed an electronic search in PubMed and SciELO on 1 April 2020, using the
following key words, grouped into three main concepts: “HTLV” AND “Peru”. Studies
collected were published from 1 January 1991 to 1 April 2020. The search was limited to
studies in humans and written in English, Spanish, Italian, or French. Additional records
were identified by means of cited reference searching and electronic searches for gray
literature (Google and Google Scholar).
We examined surveys, reports, reviews, and epidemiological studies on the prevalence
of HTLV. Titles and abstracts were screened for relevant papers, and full texts were retrieved
when appropriate. Data on the prevalence of HTLV were extracted, regardless of the type
of population (children, adults, immunosuppressed patients, etc.).
We performed a proportion meta-analysis, using the Stuart-Ord (inverse double
arcsine square root) method to calculate the 95% coefficient intervals and create the forest
plots. Heterogeneity was analyzed using the I2 statistic (StatsDirect Statstical software v.
3.3.4) [64]. The prevalence meta-analysis was presented according to six population groups:
(1) general population, (2) pregnant women or women of childbearing age, (3) sex workers,
(4) people with HIV infections, (5) MSM, (6) relatives or descendants of people infected
with HTLV, (7) people with Strongyloides infections, (8) people with tuberculosis, and (9)
blood donors. We use a random-effects (inverse variance) method.
5. Conclusions
The prevalence of HTLV-1 in the Peruvian Amazon basin is about 1.7%. Since HTLV
is endemic (prevalence > 1%) in this population of pregnant women, screening for HTLV
in prenatal care is warranted.
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